Did you mean 75 02 2?
Displaying drugs 426 - 450 of 11763 in total
Imiquimod
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that...
Approved
Investigational
Matched Iupac: … 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine …
Matched Mixtures name: … Imiquimod 5% / Levocetirizine Dihydrochloride 1% / Niacinamide 2% …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Mixtures name: … Imiquimod 5% / Levocetirizine Dihydrochloride 1% / Niacinamide 2% …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Teicoplanin
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine...
Approved
Investigational
Matched Iupac: … -trioxa-20,36,39,53,55,58-hexaazaundecacyclo[38.14.2.2^{3,6}.2^{14,17}.2^{19,34}.1^{8,12}.1^{23,27}.1 ... yl]oxy}-2-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-26,31,44,49-tetrahydroxy ... ,52S)-22-amino-5,63-dichloro-64-{[(2S,3R,4R,5S,6R)-3-decanamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2- ... -21,35,38,54,56,59-hexaoxo-47-{[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-7,13,28 …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Iupac: … (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide …
Matched Description: … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone …
Matched Salts cas: … 1042385-75-0 …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Description: … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone …
Matched Salts cas: … 1042385-75-0 …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Salmeterol
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Iupac: … 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol …
Matched Description: … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for ... [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 …
Matched Categories: … Adrenergic beta-2 Receptor Agonists ... Selective Beta 2-adrenergic Agonists …
Matched Description: … Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for ... [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 …
Matched Categories: … Adrenergic beta-2 Receptor Agonists ... Selective Beta 2-adrenergic Agonists …
Articaine
Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Approved
Matched Iupac: … methyl 4-methyl-3-[2-(propylamino)propanamido]thiophene-2-carboxylate …
Matched Mixtures name: … MAXİCAİNE 80 MG/2 ML+0,01 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN AMPUL ... ULTRAVER D-S 80 MG + 0,01819 MG / 2 ML ENJEKSİYONLUK ÇÖZELTİ, 20 ADET ... ULTRAVER D-S FORTE 80 MG + 0,03638 MG / 2 ML ENJEKSİYONLUK ÇÖZELTİ, 20 ADET …
Matched Mixtures name: … MAXİCAİNE 80 MG/2 ML+0,01 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN AMPUL ... ULTRAVER D-S 80 MG + 0,01819 MG / 2 ML ENJEKSİYONLUK ÇÖZELTİ, 20 ADET ... ULTRAVER D-S FORTE 80 MG + 0,03638 MG / 2 ML ENJEKSİYONLUK ÇÖZELTİ, 20 ADET …
Colloidal oatmeal
Colloidal oatmeal is produced by grinding fine granules of oatmeal and boiling it to extract the colloidal material. It contains high concentrations of starches and beta-glucan that exhibits water-absorbing properties. Phenols are also contained in colloidal oatmeal, which possess antioxidant and anti-inflammatory activities, as well as UV-absorbing activity. Colloidal oatmeal...
Approved
Nutraceutical
Matched Products: … Eczema Relief Soothing 2% Colloidal Oatmeal ... Eczema Relief Soothing Wash 2% Colloidal Oatmeal ... Clarisonic Mia 2 Facial Sonic Brush with First Aid Beauty Ultra Repair Skin Protectant …
Interferon alfa-n3
Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).
Approved
Investigational
Chlorpropamide
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Lactitol
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from lactose. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. sucrose). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides...
Approved
Investigational
Matched Iupac: … (2S,3R,4R,5R)-4-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexane-1,2,3,5,6-pentol …
Neisseria meningitidis serogroup b nhba fusion protein antigen
Approved
Matched Mixtures name: … BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET 2 İĞNELİ …
Neisseria meningitidis serogroup b nada protein antigen
Approved
Matched Mixtures name: … BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET 2 İĞNELİ …
Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle
Approved
Matched Mixtures name: … BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET 2 İĞNELİ …
Valdecoxib
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Categories: … COX-2 Inhibitors ... Selective Cyclooxygenase 2 Inhibitors (NSAIDs) …
Human papillomavirus type 58 L1 capsid protein antigen
Human papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. The vaccine is prepared from the purified...
Approved
Matched Mixtures name: … GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNE …
Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)
Approved
Investigational
Matched Mixtures name: … FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and BORDETELLA PERTUSSIS FIMBRIAE 2/ …
Hydroxyzine
Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine,...
Approved
Matched Iupac: … 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethan-1-ol …
Matched Salts cas: … 10246-75-0 …
Matched Products: … HIDROXIZINACLOHIDRATO 100 MG / 2 MLSOLUCION INYECTABLE …
Matched Salts cas: … 10246-75-0 …
Matched Products: … HIDROXIZINACLOHIDRATO 100 MG / 2 MLSOLUCION INYECTABLE …
Plecanatide
Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Approved
Investigational
Matched Iupac: … (4S)-4-{[(2S)-2-{[(2S)-2-amino-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-3-carboxy-1-hydroxypropylidene ... ,7S,10S,13S,16R,19S,22S,25R,32S,38R)-38-{[(1S)-1-carboxy-3-methylbutyl]-C-hydroxycarbonimidoyl}-22-(2- ... methylpropyl)-7,13-bis(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecaazabicyclo ... 3,6,9,12,15,18,21,24,30,33,36-undecahydroxy-10-[(C-hydroxycarbonimidoyl)methyl]-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2- …
Regorafenib
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Iupac: … 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide …
Matched Salts cas: … 1019206-88-2 …
Matched Salts cas: … 1019206-88-2 …
Faricimab
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … However, another set of factors, the Tie/Ang axis, comprising the transmembrane Tie-2 receptor and its ... soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced NV ... /sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, …
Antithrombin III human
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Approved
Matched Description: … A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and …
Corifollitropin alfa
Corifollitropin alfa, also known as Elonva is used in women undergoing fertility treatment to stimulate the development of more than one mature egg (oocyte) at a time in the ovaries. This drug used together with a gonadotropin-releasing hormone (GnRH) antagonist, a type of medicine also used in fertility treatments. Elonva...
Approved
Investigational
Matched Description: … Corifollitropin alfa is marketed as Elonva in more than 75 countries [L2272]. …
Calcipotriol
Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
Approved
Matched Iupac: … (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-octahydro …
Matched Mixtures name: … Calcipotriene 0.005% / Diclofenac Sodium 3% / Hyaluronic Acid Sodium Salt 2% / Niacinamide 2% …
Matched Mixtures name: … Calcipotriene 0.005% / Diclofenac Sodium 3% / Hyaluronic Acid Sodium Salt 2% / Niacinamide 2% …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). ... SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike ... overlap with that of [tixagevimab], the two can be administered to synergistically impair SARS-CoV-2 …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). ... SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike ... cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 …
Displaying drugs 426 - 450 of 11763 in total